Get More Information on Influenza Diagnostics Market - Request Sample Report
Influenza Diagnostics Market was valued at USD 1.49 billion in 2023 and is expected to reach USD 2.45 billion by 2032, growing at a CAGR of 5.69 % from 2024-2032.
The ongoing rate of infectious diseases is fueling the influenza diagnostics market. According to the National Foundation for Infectious Diseases, pneumococcal infections trigger around 150,000 hospitalizations every year, which indicates a very high rate of requirement for effective diagnostic solutions. Moreover, approximately 133 million people in the United States suffer from different chronic diseases, increasing the demand for high-quality influenza testing and faster result delivery. The increasingly problematic burden of disease underlies the imperative driving the establishment of innovative diagnostic tools in efforts to improve patient care and healthcare delivery in general.
Preparedness toward pandemics and the importance of timely surveillance systems in controlling infectious diseases have become more critical. With annual direct medical costs in the United States estimated at USD 3.2 billion, addressing influenza’s financial and health burden is a priority for governments and healthcare institutions. The market for influenza diagnostics is anticipated to grow significantly, driven by increased investments toward improving diagnostic capabilities. New point-of-care tests and advanced molecular diagnostics technologies, developed by these firms, will also leverage this trend, which shall ensure faster and more accurate detections of influenza with stronger contributions to public health efforts and better management of respiratory diseases.
DRIVERS
Advances in Diagnostic Technologies Fuel Growth in Influenza Testing Market
Advancements in diagnostic technologies, such as PCR, and rapid antigen tests open a significant growth space for the influenza diagnostics market. These enhance speed and accuracy in diagnosis while rapid antigen tests would deliver a result within 15-30 minutes; PCR tests are more expensive on an average basis, compared to the average cost of a rapid test, about USD 62.15 per patient. However, large numbers of the Ag RDTs will be introduced to the LMICs in the next six months at a maximum of USD 5 cost per test, significantly increasing access. Such cost-efficient technologies are so rapidly becoming attractive to healthcare providers, allowing for better management of patients, quicker decisions, and thereby greater demand for their implementation in clinical settings. The integration of these newly diagnosed methods into healthcare systems will further improve health outcomes and add much to the market growth as the technology develops.
Surge in Aging Population Creates Growing Need for Advanced Influenza Diagnostics
This is because the elderly population is growing geometrically; therefore, even minor proportions of this population can easily become especially vulnerable to severe complications. The global population aged 65 years and above is predicted to be over 1.5 billion in 2050. Thus, the healthcare needs that are tailored for older adults are growing in urgency every day. As a consequence, in this aspect, timely and accurate diagnosis becomes highly crucial. Various chronic conditions affect many seniors that aggravate an influenza infection, hence emergent detection becomes very crucial. This demographic trend offers deep opportunities for the marketplace of influenza diagnostics as the service providers in healthcare seek new and innovative solutions for early identification and management. Companies specializing in diagnostic tools for use in older patients can now take advantage of an emerging market to contribute to better health outcomes and responses to influenza outbreaks.
RESTRAINTS
Addressing the Accuracy Gap in Rapid Influenza Testing: Sensitivity vs. Specificity Challenges
Variability in the accuracy of the test results complicates the influenza diagnostics market. Rapid tests, for instance, offer fast turnaround times but low to moderately-low sensitivity; most rapid tests stand at 50-70% whereas their specificity is higher but stands at 95-99%. Advanced technologies, on the other hand, such as molecular testing, have much higher sensitivity and less probability of false negatives. This makes them wrongly diagnosed, deny effective care to the patient, and even lose confidence in the available diagnostic solutions. Even though rapid tests are mostly available, healthcare providers may still be reluctant to rely on them since they are suspicious of the accuracy of the given diagnosis. Remedying these issues is critical in enhancing the reliability and adoption of influenza diagnosis in the clinical environment.
Overcoming Awareness and Training Gaps in Influenza Diagnostics to Improve Patient Care
A significant restriction to influenza diagnostics is limited awareness and training. In some regions, there is a lack of basic understanding regarding the critical role that influenza diagnostics plays in effective patient management. Such a lack of understanding commonly leads to underutilizing available testing options. Healthcare providers may also not be provided with sufficient preparedness in advanced diagnostic tools, which restrains them from effectively using such technologies. The entire implementation of influenza diagnostics might be hampered by this, thus impacting patient care and the growth prospects of the market. The gaps in education have to be addressed to ensure improved uptake and efficiency of influenza testing.
BY PRODUCT
Test kits and reagents dominated the market share in 2023 for influenza diagnostics, at about 61%. This is primarily because they are highly accessible and user-friendly. Rapid Influenza Diagnostic Tests provide a highly essential advantage of point-of-care identification, ensuring timely management and treatment of influenza. They are cost-effective as well; hence, their popularity has led to vast use, particularly in resource-poor regions.
The instruments is expected to grow at the highest rate, with an estimated CAGR of 7.04% from 2024 to 2032. This mainly owes to the improvements in molecular diagnostics and automation technologies that increase both accuracy and throughput for any test. With higher accuracy and efficiency holding paramount importance in healthcare delivery, the demand for advanced diagnostic instruments will advance. Investments in the health infrastructure and further strengthening of these will strengthen growth in this segment further.
BY END USE
Hospitals and clinics continue to top the influenza diagnostics market with a 46% share of revenues that were accounted for in 2023 due to the full care of patients in these premises and readily available diagnostic testing. It is those premises with the capacity to admit patients in pretty large numbers and deliver the results of the test without any hesitation. Testing goes hand in hand with treatment as an avenue for improved patient management, which is then complemented by an improved healthcare outcome.
The diagnostic labs segment is likely to grow at the fastest rate of approximately 6.45% from 2024 to 2032. Growth in this segment is attributed to a heightened demand for specialized testing and improvements in technology that speed up and increase the accuracy of diagnoses. Enhancement of the scope of provider services based on the importance of raising precise and efficient performance in diagnostics is increasingly prompting healthcare providers to partner with diagnostic labs to further the advancements in this field. Additionally, the development of personalized medicine and custom treatment is also on the rise.
BY TEST
Traditional Flu testing diagnostics lead the market and accounted for about 65% of revenue in 2023 mainly because they are well-established and long-used, which tends to give them a preference by various healthcare providers. These tests include rapid influenza diagnostic tests and viral culture methods. They provide inexpensive results that are valid across different healthcare settings.
However, molecular influenza diagnostic tests are expected to grow at the highest CAGR of around 6.31% from 2024 to 2032, led by technological advancement, which provides greater sensitivity and specificity. Increasing recognition of the importance of accurate and timely diagnostics has vast opportunities for molecular tests. In light of that, with the current focus of healthcare systems on accurate diagnosis and prompt interventions, the demand for novel molecular testing solutions will only be able to grow further as a complement to conventional methods for improving general care for patients. This would, therefore, imply the effectiveness of a combination of treatment interventions and strategies for influenza management.
Need Any Customization Research On Influenza Diagnostics Market - Inquiry Now
In 2023, North America dominated the market for influenza diagnostics with approximately 34% revenue. It is primarily because of its developed healthcare infrastructure and huge investments going on in the area of medical technology. Moreover, North America has extensive research activities along with strong networks of healthcare providers, driving the adoption and implementation of advanced diagnostic technologies. The economic burden of influenza on the healthcare system and society is significant, with estimated overall annual costs ranging from USD 6.3 billion to USD 25.3 billion and averaging at USD 11.2 billion annually. This sizeable financial burden translates to the importance of efficient diagnostic technologies in managing outbreaks of influenza.
On the other hand, the Asia Pacific is projected to grow with the highest CAGR of around 6.65% in the forecast period from 2024 to 2032, due to increments in health accessibility, higher awareness of infectious diseases, and initiatives by the government to develop public health infrastructure. There are chances for large companies to expand their business footprint in emerging markets due to rapid growth in the demand for effective flu diagnostics. With increasingly health-conscious populations in the Asia Pacific and a need for timely diagnostic services, both traditional and molecular diagnostic technologies have the potential to thrive side-by-side with North America's well-established supremacy.
LATEST NEWS-
In October 2024, the US FDA approved prescription- and- alternative over-the-counter home use of the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, a test that uses a nasal swab that is intended for people who are having respiratory-type symptoms, identifying proteins from both SARS-CoV-2 and influenza A and B viruses within about 15 minutes.
On September 20, 2024 the FDA approved the flu vaccine given by nasal spray, FluMist for administration by a patient or patient's caregiver. It is a spray form of vaccine given intranasally and has already been approved for use in preventing influenza in patients aged between 2 and 49 years.
3M Company: 3M Molecular Diagnostics System
Abbott Laboratories: BinaxNOW Influenza A & B Card
Becton, Dickinson and Company (BD): BD Veritor System for Rapid Detection of Flu A & B
Meridian Bioscience, Inc.: ImmunoCard STAT! Flu A & B
Quidel Corporation: Sofia Influenza A+B FIA
F. Hoffmann-La Roche Ltd: cobas Influenza A/B Test
SA Scientific Ltd: Rapid Influenza Test Kit
SEKISUI Diagnostics: QuickVue Influenza A+B Test
Thermo Fisher Scientific, Inc.: TaqMan Influenza A/B PCR Test
Hologic, Inc.: Panther Fusion Influenza A/B Assay
Siemens (Germany): CLINITEK Status+ for Influenza A/B
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China): MINDRAY Rapid Test for Influenza
Koninklijke Philips N.V. (Netherlands): Philips Respironics Influenza A/B Test
NeuroLogica Corp. (U.S.): CereTom for Infectious Disease Detection
Shimadzu Medical (India) Pvt. Ltd. (Japan): PCR Detection Systems for Influenza
GENERAL ELECTRIC (U.S.): GE Healthcare Diagnostic Imaging for Influenza
Quest Diagnostics Incorporated (U.S.): Quest Influenza A & B Test
Sysmex India Pvt. Ltd. (Japan): Sysmex Flu Test
Hitachi, Ltd. (Japan): Hitachi Medical Systems for Infectious Disease Testing
Canon Inc. (Japan): Canon Medical Influenza Testing Solutions
FUJIFILM Holdings Corporation (U.K.): Fujifilm Rapid Influenza Test
GenMark Diagnostics, Inc. (U.S.): ePlex Respiratory Pathogen Panel
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 1.49 Billion |
| Market Size by 2032 | USD 2.45 Billion |
| CAGR | CAGR of 5.69 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product(Test Kit and Reagents, Instruments, Others) • By Test (Traditional Influenza Diagnostic Tests , Molecular Influenza Diagnostic Tests) • By End User(Hospitals and clinic, Diagnostic Labs, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | 3M Company, Abbott Laboratories, Becton, Dickinson and Company (BD), Meridian Bioscience, Inc., Quidel Corporation, F. Hoffmann-La Roche Ltd, SA Scientific Ltd, SEKISUI Diagnostics, Thermo Fisher Scientific, Inc., Hologic, Inc., Siemens (Germany), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp. (U.S.), Shimadzu Medical (India) Pvt. Ltd. (Japan), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex India Pvt. Ltd. (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan), FUJIFILM Holdings Corporation (U.K.), GenMark Diagnostics, Inc. (U.S.) |
| Key Drivers | • Advances in Diagnostic Technologies Fuel Growth in Influenza Testing Market. • Surge in Aging Population Creates Growing Need for Advanced Influenza Diagnostics. |
| RESTRAINTS | •Addressing the Accuracy Gap in Rapid Influenza Testing: Sensitivity vs. Specificity Challenges •Overcoming Awareness and Training Gaps in Influenza Diagnostics to Improve Patient Care |
Ans: Influenza Diagnostics Market was valued at USD1.49 billion in 2023 and is expected to reach USD 2.45 billion by 2032, growing at a CAGR of 5.69 % from 2024-2032.
Ans: The ongoing rate of infectious diseases and increasing demand for effective diagnostic solutions are key drivers.
Ans: Molecular influenza diagnostic tests are expected to grow at the highest CAGR of about 6.31% from 2024 to 2032.
Ans: Variability in test accuracy and limited awareness and training among healthcare providers are significant challenges
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7.Influenza Diagnostics Market Segmentation, by End Use
7.1 Chapter Overview
7.2 Hospitals and Clinics
7.2.1 Hospitals and Clinics Market Trends Analysis (2020-2032)
7.2.2 Hospitals and Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Diagnostic Labs
7.3.1 Diagnostic Labs Market Trends Analysis (2020-2032)
7.3.2 Diagnostic Labs Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8.Influenza Diagnostics Market Segmentation, by Product
8.1 Chapter Overview
8.2 Test Kit and Reagents
8.2.1 Test Kit and Reagents Market Trends Analysis (2020-2032)
8.2.2 Test Kit and Reagents Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Instruments
8.3.1 Instruments Market Trends Analysis (2020-2032)
8.3.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Influenza Diagnostics Market Segmentation, by Test
9.1 Chapter Overview
9.2Traditional Influenza Diagnostic Tests
9.2.1Traditional Influenza Diagnostic Tests Market Trends Analysis (2020-2032)
9.2.2Traditional Influenza Diagnostic Tests Market Size Estimates and Forecasts to 2032 (USD Million)
9.2.3.1 Rapid Influenza Diagnostic Tests (RIDTs)
9.2.3.1.1Rapid Influenza Diagnostic Tests (RIDTs)Market Trends Analysis (2020-2032)
9.2.3.1.2 Rapid Influenza Diagnostic Tests (RIDTs) Market Size Estimates and Forecasts to 2032 (USD Million)
9.2.3.2 Direct Fluorescent Antibody (DFA) Tests
9.2.3.2.1 Direct Fluorescent Antibody (DFA) Tests Market Trends Analysis (2020-2032)
9.2.3.2.2 Direct Fluorescent Antibody (DFA) Tests Market Size Estimates and Forecasts to 2032 (USD Million)
9.2.3.3 Viral Culture
9.2.3.3.1 Viral Culture Market Trends Analysis (2020-2032)
9.2.3.3.2 Viral Culture Tests Market Size Estimates and Forecasts to 2032 (USD Million)
9.2.3.4 Serological Assays
9.2.3.4.1 Viral Culture Market Trends Analysis (2020-2032)
9.2.3.4.2 Viral Culture Tests Market Size Estimates and Forecasts to 2032 (USD Million)
9.3Molecular Influenza Diagnostic Tests
9.3.1Molecular Influenza Diagnostic Tests Market Trends Analysis (2020-2032)
9.3.2Molecular Influenza Diagnostic Tests Market Size Estimates and Forecasts to 2032 (USD Million)
9.3.3.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
9.3.3.1.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR) Market Trends Analysis (2020-2032)
9.3.3.1.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) Market Size Estimates and Forecasts to 2032 (USD Million)
9.3.3.2 Isothermal Nucleic Acid Amplification Tests (INAAT)
9.3.3.2.1Isothermal Nucleic Acid Amplification Tests (INAAT)Market Trends Analysis (2020-2032)
9.3.3.2.2 Isothermal Nucleic Acid Amplification Tests (INAAT)Market Size Estimates and Forecasts to 2032 (USD Million)
9.3.3.3 Loop-Mediated Isothermal-based Amplification Assays
9.3.3.3.1 Loop-Mediated Isothermal-based Amplification Assays Market Trends Analysis (2020-2032)
9.3.3.3.2 Loop-Mediated Isothermal-based Amplification Assays Market Size Estimates and Forecasts to 2032 (USD Million)
9.3.3.4 Transcription Mediated Isothermal-based Amplification Assays
9.3.3.4.1Transcription Mediated Isothermal-based Amplification Assays Market Trends Analysis (2020-2032)
9.3.3.4.2Transcription Mediated Isothermal-based Amplification Assays Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.2.4 North America Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.5 North America Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.2.6.2 USA Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.6.3 USA Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.2.7.2 Canada Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.7.3 Canada Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.2.8.2 Mexico Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.8.3 Mexico Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.6.2 Poland Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.6.3 Poland Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.7.2 Romania Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.7.3 Romania Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.8.2 Hungary Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.8.3 Hungary Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.9.2 Turkey Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.9.3 Turkey Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.4 Western Europe Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.5 Western Europe Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.6.2 Germany Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.6.3 Germany Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.7.2 France Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.7.3 France Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.8.2 UK Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.8.3 UK Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.9.2 Italy Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.9.3 Italy Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.10.2 Spain Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.10.3 Spain Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.13.2 Austria Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.13.3 Austria Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.4 Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.5 Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.6.2 China Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.6.3 China Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.7.2 India Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.7.3 India Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.8.2 Japan Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.8.3 Japan Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.9.2 South Korea Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.9.3 South Korea Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.10.2 Vietnam Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.10.3 Vietnam Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1Singapore Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.11.2 Singapore Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.11.3 Singapore Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.12.2 Australia Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.12.3 Australia Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.4 Middle East Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.5 Middle East Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.6.2 UAE Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.6.3 UAE Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.7.2 Egypt Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.7.3 Egypt Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.9.2 Qatar Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.9.3 Qatar Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.2.4 Africa Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.5 Africa Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.2.6.2 South Africa Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.6.3 South Africa Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Influenza Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.6.4 Latin America Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.5 Latin America Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.6.6.2 Brazil Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.6.3 Brazil Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.6.7.2 Argentina Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.7.3 Argentina Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.6.8.2 Colombia Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.8.3 Colombia Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Influenza Diagnostics Market Estimates and Forecasts, by End Use (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Influenza Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Influenza Diagnostics Market Estimates and Forecasts, by Test (2020-2032) (USD Million)
11. Company Profiles
11.1 3M Company
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Meridian Bioscience, Inc.:
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Quidel Corporation
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 F. Hoffmann-La Roche Ltd
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 SEKISUI Diagnostics:
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Siemens (Germany)
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 GENERAL ELECTRIC (U.S.)
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Quest Diagnostics Incorporated
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Hitachi, Ltd
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
Test Kit and Reagents
Instruments
Others
By End-use
Hospitals and clinic
Diagnostic Labs
Others
By Test
Traditional Influenza Diagnostic Tests
Rapid Influenza Diagnostic Tests (RIDTs)
Direct Fluorescent Antibody (DFA) Tests
Viral Culture
Serological Assays
Molecular Influenza Diagnostic Tests
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Isothermal Nucleic Acid Amplification Tests (INAAT)
Loop-Mediated Isothermal-based Amplification Assays
Transcription Mediated Isothermal-based Amplification Assays
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
Stomach Cancer Treatment Market was valued at USD 4.84 Bn in 2023, and is expected to reach USD 15.04 Bn by 2032, growing at a CAGR of 13.45% from 2024-2032.
The Varicose Veins Treatment Market size was valued at USD 1.42 billion in 2023 and is expected to reach USD 2.53 billion by 2032 and grow at a CAGR of 6.64% over the forecast period 2024-2032.
The Corporate Wellness Market Size was valued at USD 64.11 billion in 2023 and will reach USD 123.35 billion in 2032, with a CAGR of 7.60% by 2024-2032.
The Surgical Sutures Market size was projected at USD 4.55 billion in 2023 and is anticipated to reach USD 7.18 billion by 2032 at a CAGR of 5.2% over the forecast period of 2024-2032.
The Annuloplasty System Market size was valued at USD 450 Million in 2023 and is expected to reach USD 695.57 Million by 2032 and grow at a CAGR of 4.98% over the forecast period 2024-2032.
The Animal Genetic Market was estimated at USD 6.5 billion in 2023 and is poised to reach USD 11.59 billion in 2031 anticipated to expand at a compound annual growth rate CAGR of 7.5% for the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
